Xvivo Perfusion AB is a medical technology company that specializes in providing solutions for organ transplantation and preservation. The company's values revolve around innovation, patient focus, and quality. Xvivo Perfusion AB's corporate philosophy is centered on improving patient outcomes by developing and commercializing advanced products and services that ensure the safe and effective transport and preservation of organs. With a strong commitment to excellence and continuous improvement, Xvivo Perfusion AB strives to be a leader in the field of organ transplantation, contributing to the advancement of medical science and ultimately saving lives.

Xvivo Perfusion AB is primarily present in several countries and regions around the world. With a global presence, the company operates in Europe, North America, Latin America, and Asia-Pacific. Its reach extends to countries such as Sweden, the United States, Germany, France, the United Kingdom, Canada, Brazil, Australia, and many more. Xvivo Perfusion AB has established a strong international footprint, allowing it to cater to a diverse range of markets and provide its innovative perfusion solutions to healthcare professionals worldwide.

Some significant milestones achieved by Xvivo Perfusion AB include the development and commercialization of the XPS system, a medical device used for ex-vivo perfusion of organs. The company successfully received clearance from the FDA in 2014 to market the XPS system in the United States, significantly expanding its reach. In 2016, Xvivo Perfusion achieved another milestone by conducting the first-ever transplantation of human lungs, which were perfused and evaluated using their XPS system. These achievements demonstrate the company's expertise in the field of organ preservation and transplantation, positioning Xvivo Perfusion AB as a key player in advancing medical technologies for organ transplant procedures.

Xvivo Perfusion AB is a renowned medical technology company specializing in solutions for organ transplantation. Established in 1998, Xvivo Perfusion has been a trusted name in the industry. The company focuses on developing advanced systems and solutions for organ preservation and evaluation prior to transplantation, ensuring optimal outcomes for patients and healthcare professionals alike. With its innovative technology and dedication to improving transplantation processes, Xvivo Perfusion has gained significant recognition globally. This Swedish-based company continues to play a vital role in advancing organ transplantation practices and contributing to enhanced patient care worldwide.

The main competitors of Xvivo Perfusion AB in the market include Organ Recovery Systems, XVIVO Surgical AB, TransMedics Group Inc., and OrganOx Limited.

Xvivo Perfusion AB is primarily active in the healthcare and medical device industries.

Xvivo Perfusion AB specializes in providing innovative solutions for organ transplantation and advanced organ preservation. Their business model revolves around developing and commercializing state-of-the-art medical technology and systems that enable better organ transportation and preservation. Xvivo Perfusion AB offers products like the XPS™ (Xvivo Perfusion System), which enables safe evaluation and preservation of donor organs, and STEEN Solution™, a cold perfusion system used for lung preservation. By focusing on improving transplantation outcomes and extending organ viability, Xvivo Perfusion AB plays a crucial role in the organ transplantation field.

Коефициентът на цена спрямо печалбата (КЦП) на Xvivo Perfusion е 102,19.

Коефициентът на цена към оборот (KUV) на Xvivo Perfusion е 15,52.

AlleAktien качественият резултат за Xvivo Perfusion е 4/10.

очаквана Xvivo Perfusion оборотът е 868,66 млн. SEK.

очаквана Xvivo Perfusion печалба е 131,97 млн. SEK.

Xvivo Perfusion AB is a leading company in the development and manufacturing of products for organ perfusion that save lives. The company was founded in 1998 in Gothenburg, Sweden and employs over 230 employees worldwide. The company's business model is based on the production and marketing of clinical perfusion products for transplantation. The product range includes, among others, the XPS (Xvivo Perfusion System), a system for machine perfusion preparation and support of organs before transplantation. The company is particularly strong in the field of lung and liver perfusion and has brought several successful products to the market in this area. One of the new products is the Perfusix, a machine for the preparation of lungs that allows the use of organs from different sources and their evaluation before transplantation. The company is highly respected by customers due to its excellent performance and high product quality. Xvivo Perfusion AB follows a vertical business approach, fulfilling the needs of its customers through the development and production of clinical products for organ preparation. The customers are mainly transplant clinics that use the XPS to improve organ quality and increase patient survival rates. In addition, Xvivo Perfusion AB offers excellent training and consulting services to help customers maximize the full potential of their products. This extends the lifespan of the products and enables the market entry of new products. The company also has a strong commitment to research and development. They have partnerships with leading research institutes around the world to further enhance the performance of their products. This collaboration also provides an opportunity to develop new products and expand into other application areas. Overall, the business model of Xvivo Perfusion AB is very solid and tailored to the needs of customers. Through the development of new products and collaboration with research and development partners, the company is well positioned to expand its performance offering and meet the needs of customers.

Xvivo Perfusion разпределя дивидента от 0 SEK на плащания годишно.

Дивидентата за Xvivo Perfusion в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Xvivo Perfusion е SE0004840718.

WKN на Xvivo Perfusion е A1J5GZ.

Тикерът на Xvivo Perfusion е XVIVO.ST.

През последните 12 месеца Xvivo Perfusion изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Xvivo Perfusion да изплати дивиденда в размер на 0 SEK.

Дивидентната доходност на Xvivo Perfusion в момента е .

Xvivo Perfusion изплаща дивидент на тримесечие. Той се разпределя в месеците .

Xvivo Perfusion платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 SEK. Това съответства на дивидентна доходност от 0 %.

Xvivo Perfusion се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Xvivo Perfusion на 9.11.2024 г. в размер на 0 SEK, трябваше да притежавате акцията в портфейла си преди Ex-деня на 9.11.2024 г..

Последното дивидентно плащане беше извършено на 9.11.2024 г..

През година 2023 Xvivo Perfusion изплати 0 SEK под формата на дивиденти.

Дивидентите от Xvivo Perfusion се изплащат в SEK.